Winslow Evans & Crocker’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $167K | Buy |
1,285
+185
| +17% | +$24K | 0.03% | 357 |
|
|
2020
Q3 | $160K | Sell |
1,100
-300
| -21% | -$43.6K | 0.04% | 297 |
|
|
2020
Q2 | $207K | Hold |
1,400
| – | – | 0.06% | 268 |
|
|
2020
Q1 | $154K | Hold |
1,400
| – | – | 0.05% | 268 |
|
|
2019
Q4 | $162K | Hold |
1,400
| – | – | 0.04% | 311 |
|
|
2019
Q3 | $114K | Sell |
1,400
-60
| -4% | -$4.89K | 0.03% | 369 |
|
|
2019
Q2 | $106K | Hold |
1,460
| – | – | 0.03% | 388 |
|
|
2019
Q1 | $138K | Sell |
1,460
-50
| -3% | -$4.73K | 0.04% | 328 |
|
|
2018
Q4 | $112K | Sell |
1,510
-200
| -12% | -$14.8K | 0.04% | 336 |
|
|
2018
Q3 | $150K | Hold |
1,710
| – | – | 0.05% | 302 |
|
|
2018
Q2 | $170K | Buy |
1,710
+250
| +17% | +$24.9K | 0.05% | 285 |
|
|
2018
Q1 | $174K | Hold |
1,460
| – | – | 0.06% | 273 |
|
|
2017
Q4 | $185K | Buy |
1,460
+60
| +4% | +$7.62K | 0.06% | 270 |
|
|
2017
Q3 | $164K | Sell |
1,400
-35
| -2% | -$4.11K | 0.05% | 285 |
|
|
2017
Q2 | $114K | Sell |
1,435
-1
| -0.1% | -$80 | 0.03% | 412 |
|
|
2017
Q1 | $73.5K | Buy |
1,436
+250
| +21% | +$12.8K | 0.02% | 462 |
|
|
2016
Q4 | $44.4K | Buy |
1,186
+136
| +13% | +$5.09K | 0.01% | 561 |
|
|
2016
Q3 | $71.2K | Hold |
1,050
| – | – | 0.02% | 469 |
|
|
2016
Q2 | $58.3K | Hold |
1,050
| – | – | 0.02% | 481 |
|
|
2016
Q1 | $65.9K | Hold |
1,050
| – | – | 0.02% | 446 |
|
|
2015
Q4 | $98.8K | Hold |
1,050
| – | – | 0.03% | 396 |
|
|
2015
Q3 | $84.4K | Hold |
1,050
| – | – | 0.03% | 416 |
|
|
2015
Q2 | $126K | Hold |
1,050
| – | – | 0.04% | 383 |
|
|
2015
Q1 | $110K | Hold |
1,050
| – | – | 0.03% | 410 |
|
|
2014
Q4 | $102K | Sell |
1,050
-100
| -9% | -$9.7K | 0.03% | 411 |
|
|
2014
Q3 | $89.8K | Hold |
1,150
| – | – | 0.03% | 442 |
|
|
2014
Q2 | $72.6K | Sell |
1,150
-100
| -8% | -$6.32K | 0.02% | 433 |
|
|
2014
Q1 | $83.9K | Hold |
1,250
| – | – | 0.03% | 394 |
|
|
2013
Q4 | $80K | Buy |
+1,250
| New | +$80K | 0.03% | 427 |
|